Cargando…

Aberrations in Angiogenic Signaling and MYC Amplifications are Distinguishing Features of Angiosarcoma

Angiosarcomas are very aggressive, rare malignant tumors that originate from vascular or lymphatic vessels and primarily occur following chemical exposure or radiation therapy. Tumor response to either chemotherapy, radiation, or novel anti-angiogenic therapeutics is very low, and because little is...

Descripción completa

Detalles Bibliográficos
Autores principales: Kurisetty, Vittal, Bryan, Brad A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4217701/
https://www.ncbi.nlm.nih.gov/pubmed/25374893
http://dx.doi.org/10.4172/2329-9495.1000102
_version_ 1782342429318316032
author Kurisetty, Vittal
Bryan, Brad A
author_facet Kurisetty, Vittal
Bryan, Brad A
author_sort Kurisetty, Vittal
collection PubMed
description Angiosarcomas are very aggressive, rare malignant tumors that originate from vascular or lymphatic vessels and primarily occur following chemical exposure or radiation therapy. Tumor response to either chemotherapy, radiation, or novel anti-angiogenic therapeutics is very low, and because little is known regarding the aberrant signaling that controls these tumors, personalized treatment options for many of these patients are lacking. In this review, we summarize several recent findings regarding the genomics of angiosarcomas, including new discoveries regarding aberrant angiogenic signaling and Myc amplification as key features of this tumor type.
format Online
Article
Text
id pubmed-4217701
institution National Center for Biotechnology Information
language English
publishDate 2013
record_format MEDLINE/PubMed
spelling pubmed-42177012014-11-03 Aberrations in Angiogenic Signaling and MYC Amplifications are Distinguishing Features of Angiosarcoma Kurisetty, Vittal Bryan, Brad A Angiol Open Access Article Angiosarcomas are very aggressive, rare malignant tumors that originate from vascular or lymphatic vessels and primarily occur following chemical exposure or radiation therapy. Tumor response to either chemotherapy, radiation, or novel anti-angiogenic therapeutics is very low, and because little is known regarding the aberrant signaling that controls these tumors, personalized treatment options for many of these patients are lacking. In this review, we summarize several recent findings regarding the genomics of angiosarcomas, including new discoveries regarding aberrant angiogenic signaling and Myc amplification as key features of this tumor type. 2013-04-08 /pmc/articles/PMC4217701/ /pubmed/25374893 http://dx.doi.org/10.4172/2329-9495.1000102 Text en Copyright: © 2013 Kurisetty V, et al. http://creativecommons.org/licenses/by/2.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Article
Kurisetty, Vittal
Bryan, Brad A
Aberrations in Angiogenic Signaling and MYC Amplifications are Distinguishing Features of Angiosarcoma
title Aberrations in Angiogenic Signaling and MYC Amplifications are Distinguishing Features of Angiosarcoma
title_full Aberrations in Angiogenic Signaling and MYC Amplifications are Distinguishing Features of Angiosarcoma
title_fullStr Aberrations in Angiogenic Signaling and MYC Amplifications are Distinguishing Features of Angiosarcoma
title_full_unstemmed Aberrations in Angiogenic Signaling and MYC Amplifications are Distinguishing Features of Angiosarcoma
title_short Aberrations in Angiogenic Signaling and MYC Amplifications are Distinguishing Features of Angiosarcoma
title_sort aberrations in angiogenic signaling and myc amplifications are distinguishing features of angiosarcoma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4217701/
https://www.ncbi.nlm.nih.gov/pubmed/25374893
http://dx.doi.org/10.4172/2329-9495.1000102
work_keys_str_mv AT kurisettyvittal aberrationsinangiogenicsignalingandmycamplificationsaredistinguishingfeaturesofangiosarcoma
AT bryanbrada aberrationsinangiogenicsignalingandmycamplificationsaredistinguishingfeaturesofangiosarcoma